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ABSTRACT  
In situ gel with ion activated system which occurs as triggered by a change in the ionic strength. Osmotic gradient is a factor that determines the rate 
of gelation on the surface of the gel. Polymers play an important role in drug delivery from their dosage forms. Polymeric in gelling systems provides 
longer drug release compared to conventional delivery systems. The use of biodegradable and biocompatible polymers for in situ gel formulation 
makes the drug delivery system acceptable and controlled. Thus the continuous and prolonged release of the drug, biocompatibility characteristics 
makes the dose gel form in situ reliable. Polymers that are used in ion activated in situ gelation can be various, such as gelrite gellan gum, alginates, 
deacetylated gellan gum, anionic polymers (carbopol), cationic polymer (chitosan), non-ionic polymers (HPMC, Methylcellulose), thiolated polymer 
(thiomers), carbomer (polymer used in ophthalmic), polycarbophil (polymer used in ophthalmic). This review is written based on the data or 
information obtained by using several search engines and several scientific journals, using the keywords in situ gel with polymers, ion activated the 
system, and limited search years in 2010 and above.  
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The goal of pharmacotherapeutics is to treat a disease in a consistent 
and predictable fashion. In topical application, the drops provide 
therapeutically effective concentrations that have been the preferred 
route of administration for bacterial conjunctivitis and keratitis 
because the drops wash away bacteria and bacterial antigens; 
adverse systemic effects of the drugs are decreased or eliminated 
[1]. The drug development with new dosage forms has always been 
done to provide effective and easy to use by patients. In addition, the 
presence of new drug preparations may increase bioavailability and 
reduce side effects. One of the discovery is a breakthrough of gel 
preparations with unique characteristics, such as in situ gel. Over the 
last decades, an impressive number of novel temperature, pH, and 
ion-induced in situ forming solutions have been described in the 
literature. Each system has its own advantages and drawbacks. The 
choice of particular hydrogels depends on its intrinsic properties 
and investigated therapeutic use [2]. 
The ocular residence time of the drug needs to increase for the ocular 
bioavailability of drug that increases. In situ forming gels are 
formulations, where they undergo a transition into a gel, conveniently 
dropped in the eye, applied as a solutions [3, 4], or suspensions. In situ 
gelling systems developing are to prolong the precorneal residence time 
of a drug, consequently, enhance ocular bioavailability, and improve 
patient compliance. The in situ gel are more acceptable for the patients 
and has been the most attractive feature systems caused of the 
precorneal residence time of some in situ gelling for several hours [5].  
The cornea as the main barrier for the ocular absorption of drugs, 
where is that acts as a barrier for penetration of hydrophilic drug is 
the outer epithelium layer while that acts as a barrier for the 
hydrophobic drug is the inner stroma. Develop an ophthalmic novel 
drug system without damaging the natural mechanism and barriers 
of the eyes at the same time achieving affective ocular drug 
concentration at the site of action while improving the residence 
time of drugs in eyes is the solution for the small portion drug will 
be lost on the anterior segment of the eyes [6].  
The advantages of in-situ forming polymeric delivery systems are ease 
and reduced frequency of application, comfort, and improved patient 
compliance [7]. In situ gel formation occurs due to one or combination 
of different stimuli like pH change, temperature modulation using 
polymers, solvent exchange employing polymers [7], fungal keratitis 
that must be diagnosed and treated affectively, previous ocular surface 
disease and trauma as the leading causes of fungal infection in the 
cornea, prolonged chemo-or immune-suppressive therapy, contact 
lens use, current therapeutic options are limited, and oral therapy 
requires high doses of antifungal agents which may cause unwanted 
side effects so by use of in situ gels can resolve the problem of short 
residence time of formulations on the eye surface [8]. 
In situ gel with ion activated system 
Ion activated systems  
Polymers may undergo a phase transition in the presence of various 
ions. Some of the polysaccharides fall into the class of ion-sensitive 
polymers. Alginate is used as the gelling agent in combination with 
Hydroxy Propyl Methyl Cellulose/HPMC (Methocel E50Lv) which 
acted as a viscosity enhancing agent. Gelrite gellan gum, a novel 
ophthalmic vehicle that gels in the presence of mono or divalent 
cations, present in the lachrymal fluid can be used alone and in 
combinations with sodium alginate as the gelling agent. Gelrite is an 
anionic polysaccharide that undergoes in situ gelling in the presence 
of mono and divalent cations, especially Ca2+
 
. Likewise, alginic acid 
undergoes gelation in presence of divalent/polyvalent cations due to 
the interaction with guluronic acid block in alginate chains [9]. 
Table 1: Various in situ gel mechanisms along with the polymer 
External stimuli Mechanism Examples of polymer References 
Temperature 
dependent system 
Formulation is liquid at room temperature (20-25 °C) which 




pH-triggered system  
 
Phase transition occur due to rise in pH from 4.2 to 7.4  
 
Pseudolatexes, Carbomer (Acrylic acid) 
Cellulose acetate phthalate latex 
1,2,3,7 
Ion activated system  
 
Formulation undergoes liquid-gel transition under the 
influence of an increase in ionic strength  
Chitosan, Gellan gum/Gelrite, Alginate 
 
1,2,3,7,9 
From table above, we know that polymers used in ion activated system were chitosan, gallen gum, and alginate. Which mechanism is undergoing 
liquid-gel transition under the influence of an increase in ionic strength [1]. 
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Reported ophthalmic in situ gel with ion activated system 
Polymers that are used in ion activated in situ gelation can be 
various, such as gelleriete gellan gum, alginates, deacetylated gellan 
gum, anionic polymers (carbopol), cationic polymer (chitosan), non-
ionic polymers (HPMC, Methylcellulose), thiolated polymer 
(thiomers), carbomer (polymer used in ophthalmic), polycarbophyl 
(polymer used in ophthalmic) and many more.  
Placebo in situ gelling systems were prepared using different polymer 
ratios and evaluated for their gelling capacity to identify a suitable 
composition. Chitosan was dissolved in acetate buffer, pH 5.5–6.0. 
Gellan gum was dissolved in ultrapure water with heating at 70–80 °C 
with stirring. The gelling capacity was determined by placing a drop of 
the system in a vial containing 2 ml of freshly prepared simulated tear 
fluid (STF) using sodium chloride 0.670 g, sodium bicarbonate 0.200 g, 
calcium chloride dihydrate 0.008 g and purified water q. s. 100 g and 
visually assessing the gel formation, noting the time taken for gelation 
and time taken by the formed gel to dissolve [10].  
The formulation and evaluation of in situ ocular gelling systems (ion 
activated gelling systems) of Ketorolac tromethamine have done. 
These gelling systems involve the use of Gelrite as polymer. They 
evaluated the formulation for clarity, pH measurement, gelling 
capacity, drug content estimation, rheological study, in vitro drug 
release, ocular irritancy studies (as per draize test) and ex-vivo 
corneal permeation studies using isolated goats cornea. The 
developed formulations showed the sustained release of drug for up 
to 6 h. The formulations were found to be non-irritating with no 
ocular damage [11]. 
The preparation and characterization of in situ gel were performed 
using chitosan (water soluble) and sodium glycerophosphate was 
dissolved in distilled water separately at room temperature. 
Complete solvation was achieved by placing the solutions in the 
refrigerator for 2 h. The glycerophosphate solution was then added 
dropwise into the chitosan solution with constant stirring. 
Pilocarpine hydrochloride (2% w/v) was dissolved in small volume 
of distilled water and then added to the polymeric solution with 
stirring. The stirring was continued for 10 min to gain homogenous 
mixture. Benzalkonium chloride was added as a preservative in the 
preparation. The sterilization was carried out by exposing in situ gels 
filled in glass vials to ultraviolet (UV) radiations in a UV chamber for 
a period of 60 min at room temperature (25 °C) in air. The 
characterization that done were gelation temperature, gelation time, 
isotonicity test, determination of viscosity, determination of drug 
content, in vivo and in vitro studies [12].  
In situ gel from Sesbania grandiflora flower extract for the treatment 
of bacterial conjunctivitis was prepared and evaluated too. For the 
preparation of gel dispersed the required amount of Pluronic F127 
and chitosan was dispersed in cold distilled water and 0.2% acetic 
acid stirred it for 1 hour. Pluronic solution was placed in the 
refrigerator until it dissolves completely. The extract was weighed 
and dissolved it in a small amount of water. Chitosan solution and 
solution of extract was added and stirred it vigorously for 1 hour. 
After that, the remaining ingredients were added while stirring. 
They prepared the gel containing a various concentration of extract 
and the formulation codes are from G1 to G6. Evaluation that done 
were physical evaluation, measurement of pH, gelling capacity, 
gelation temperature and rheological study [13].  
Cao et al. has prepared ion-activated in situ gel systems of 
scopolamine hydrobromide and evaluated its anti-motion sickness 
efficacy. Preparation of nasal formulations A certain amount of 
gellan gum was added to deionized water and dissolved by heating 
to 100 °C with moderate stirring. After cooling to below 40 °C, 
Scopolamine (SCOP) (0.4%, w/v), mannitol (5%, w/v), and 
chlorhexidine acetate (0.01%, w/v) were added and mixed well. 
Three kinds of SCOP in situ gels were prepared at the concentrations 
of gellan gum which were 0.2%, 0.5%, and 1.0% (w/v), respectively. 
The pH of all the formulations was between 4.0 and 6.0 [14].  
Balasubramaniam and Pandit prepared and evaluated ion-activated 
in situ gelling systems for sustained ophthalmic delivery of 
ciprofloxacin hydrochloride (CPH). The preparation was: gellan 
alone and its combinations with sodium alginate, with or without 
sodium citrate (20% w/w), were dissolved in hot acetate buffer (70 
°C, prepared in fresh water for injection under laminar flow) pH 5.0 
by continuous stirring at 40 °C. The required quantity of CPH to give 
a final drug concentration of 0.3% w/v was added to the polymeric 
solution and stirred until dissolved. The formulations were filled in 
10 ml amber colored glass vials, capped with rubber closures, and 
sealed with aluminum caps. The formulations, in their final pack, 
were terminally sterilized by autoclaving at 121 °C and 15 psi for 20 
min. The sterilized formulations were stored in a refrigerator (4–8 
°C) until further use. The evaluation that done were drug content 
uniformity, gelation studies, rheological studies, in vitro release 
studies, antimicrobial efficacy studies, in vivo rabbit eye study [15]. 
Swapnil et al. designed and evaluated Ion Induced in situ gel 
formulation for levofloxacin hemihydrate ocular delivery. This type 
of formulation was prepared in deionized water as the gelling agent 
forms a stiff gel when interact with the ions in the buffer system. 
Take 0.9% w/v of sodium chloride and add this under constant 
stirring, then add benzalkonium chloride (0.02% w/v) to above the 
solution as a preservative. After that add levofloxacin solution (0.5% 
w/v) in polymer solution under stirring to form uniform solution 
and lastly make up the volume up to 100 ml. Formulations were 
tested for ocular irritation study [16].  
Sneha et al. prepared and evaluated ion activated in situ gel of gellan 
gum containing salbutamol sulphate for nasal administration. The 
preparation was accurately weighed the quantity of gellan gum (0.2–
0.5% w/v) was dispersed in distilled water. The dispersions were 
then stirred for 20 min at 85–90 °C using magnetic stirrer and then 
cooled to room temperature. HPMC E15 was added slowly with 
stirring. d-mannitol, benzalkonium chloride and Tween 80 were also 
added simultaneously. Finally, salbutamol sulphate was added with 
stirring. The pH of all formulations was in the range of 4.5–6.5. 
Formulations were filled in amber colored glass vials, capped with 
rubber closures and sealed with aluminium caps. Formulations were 
stored in a refrigerator (4–8 °C) until further use. Evaluation that 
done were in vitro gelation study, viscosity measurements, drug 
content determination, gel strength determination, in vitro 
mucoadhesive strength, in vitro drug release study, ex vivo 
permeation study, histopathological studies, stability study [17]. 
Polymers play an important role in drug delivery from their dosage 
forms. Polymeric in gelling systems provides longer drug release 
compared to conventional delivery systems. A variety of synthetic, 
synthetic polymers are developed for controlled drug release. The 
use of biodegradable and biocompatible polymers for in situ gel 
formulations makes the drug delivery system acceptable and 
controlled. Thus the continuous and prolonged release of the drug, 
the biocompatibility characteristics make the dose gel form in situ 
reliable. In the latest technology, the polymer combination focuses 
on the development of safe ophthalmic delivery systems [18].  
Polymers that are used in ion activated in situ gelations can be 
various, such as gelleriete gellan gum, alginates [19], deacetylated 
gellan gum, anionic polymers (carbopol), cationic polymer 
(chitosan), non-ionic polymers (HPMC, Methylcellulose), thiolated 
polymer (thiomers) [20], carbomer (polymer used in ophthalmic), 
polycarbophil (polymer used in ophthalmic) [21,22], and many 
more.  
Gellan gum is anionic heteropolysaccharide, which forms a clear gel 
in the presence of mono ordicalent cations. The electrolytes of the 
tear fluid and especially Na+
Sodium alginate is a natural hydrophilic sodium salt of alginic acid 
and forms three-dimensional hydrogel matrics with low viscosity, 
free-flowing liquid at concentrations suitable for gel formation in the 
lachrymal fluid. Alginate changes into the stable gel phase due to 
ionic crosslinking of alginate chains with tear ca 2+. To decrease the 
amount of alginate required for gelation, HPMC was mainly used as 
viscosity enhancer [22].  
, Ca2+and Mg2+cations are particularly 
suited to initiate gelation of the polymer when instilled as a liquid 
solution into the cul-de-sac. There is cross-linking of negatively 
charged polysaccharide and cations. Once gelled, the formulation 
resists the natural drainage process from the precorneal area [20].  
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Every polymers are made in situ hydrogel dosage form as its base in 
some different formulation. These polymers are tested and determine 
the best polymers formulation for this dosage form through some 
evaluation, such as physical parameters, gelling capacity, rheological 
studies, in vitro drug release studies, texture analysis, isotonicity 
evaluation, ocular irritancy test, accelerated stability studies, sterility 
studies, sol-gel transition temperature and gelling time [19, 23], gelling 
ability, drug content, swelling studies, FTIR [21, 22], permeation 
studies across a sheep’s corneal membrane [21]. 
In the case of gellan containing preparations, increasing the 
concentration of gellan beyond 0.0625% caused gelation upon 
cooling to 40 °C (during stirring). The ionic content of the vehicle 
used, in this case, acetate buffer pH 5.0, and the presence of HCl in 
CPH could have contributed to the gelation of gellan when used 
beyond 0.0625% (used in this study). In the combination systems 
with sodium alginate, the concentration of gellan was kept constant 
at 0.03% and the concentration of sodium alginate was varied to 
give a maximum of 1% polymer concentration since an increase in 
total polymer concentration beyond 1% resulted in gelation during 
formulation [8]. The rheological studies result showed that gellan 
alone didn't make any change in viscosity after autoclaving, in the 
other hand, the formulation contains a combination of sodium 
alginate and gellan showed around 10-15% reduction in viscosity 
after autoclaving. The in vitro release study of all concentration 
showed that the amount of drug released in the first minute 
decreased with increasing polymer concentration and this trend 
continued for the entire duration of the study. The last test is in vivo 
rabbit eye studies. The tested formulations showed a markedly 
improved effect when compared with the marketed (standard) eye 
drop. The formulations were successful in inhibiting the growth for 
the entire duration of the study in all the animals infected with P. 
aeruginosa. The formulations used for the in vivo study formed a 
translucent gel immediately after installation into the eye. Gross 
examination of the ocular tissues showed that the formulations did 
not cause undue irritation and no leakage of the gelled material was 
seen from any part of the eye [15]. 
The study of using a combination of 0.5% gellan gum and 0.25% 
chitosan as the polymer for in situ gel base was done. Chitosan is 
reported to act as penetration enhancers that increase transcorneal 
permeation of the drug. Besides this, its other properties like 
bioadhesiveness, viscous nature, and ability to convert into a 
hydrogel at pH>6.5 make it the best suitable candidate for the 
development of this type of delivery systems [24]. Interaction 
studies were carried out to check any possible interaction between 
formulation ingredients. UV spectra obtained before and after 
autoclaving were found to be identical. No additional peak emerged 
or shift in the existing peak occurred. It revealed that the ingredients 
were compatible to each other and no physicochemical reactions 
took place. Ocular irritation of the developed formulation was 
checked by Hen’s egg chorioallantoic membrane test which is a 
rapid, sensitive, and inexpensive test. Testing with incubated eggs is 
a borderline case between in vivo and in vitro systems and does not 
conflict with the ethical and legal obligations. This study showed 
that the formulation was non-irritant to mild irritant and it's well 
tolerable [10]. 
Many studies about in situ gel with ion activated systems. Research 
about development and characterization of in situ gel for an 
ophthalmic formulation containing ciprofloxacin hydrochloride 
showed in the FTIR that no interaction between polymer and 
ciprofloxacin HCl drugs. The pH of the gel solution in situ was found 
to be about 6.49-6.58 for all formulations. The IG 3 formulation 
(sodium alginate: HPMC = 1.5:0.5) has 6.53 pH which is an acceptable 
range for eye preparations. Rheology research showed that HPMC 
addition showed good results ciprofloxacin HCl was successfully 
formulated as in situ gel-forming eye drops using Na-alginate and 
HPMC which can increase bioavailability and patient compliance. 
Physicochemical characterization research and drug release in vitro 
indicate that the development of developed formulations can be an 
alternative to conventional eye drops and ointments in ease and with 
the added benefit of sustain released resulting in improved patient 
compliance [25].  
In the research of formulation and evaluation in situ mucoadhesive 
ophtalmic hydrogels for sustained delivery of pefloxacin mesylate, 
optimation of in situ gel with ion activated the system from 
pefloxacin mesylate can be formulated using a combination of 
sodium alginate and hydroxyethylcellulose. Liquid formulation at 
non physiological pH [pH 5] and experiencing rapid gelation at 
physiological pH [pH 7.4]. That experiment showed it has good 
bioadhesive, viscosity and kinetic release research showed sustained 
release in 1 period of 12 h followed by reaction of order 0. Isotonic 
optimized formulation, not irritate, and showed antimicrobial 
efficacy. It can be concluded that the formulations obtained show 
that the preparation of the formulation is easily managed in the form 
of drops undergoing a transition phase to form a viscellable gel 
whose residence time is precorneally increased and the drug lasts 
for a longer time [26].  
Salunke and Patil said that deacetylated gellan gum was selected in 
comparison with high acetylated form because it has desirable 
properties such as responsible for ion activated gelation, having low 
viscosity, clear in clarity, firm and brittle structure. All gellan gum 
formulations showed immediate gelation within a period of 10-15 
seconds, depending upon the concentration of gellan gum used. The 
formulation containing 0.3 % and 0.4 % of gellan gum showed 
optimum gelation but the formulation containing 0.3 % of gellan 
gum showed satisfactory viscosity for spraying as a droplet, so the 
0.3 % of gellan gum in the formulation showed optimum viscosity in 
the sol-gel transition state. This formulation was also safe to the 
surface of epithelium lineng and the granular cellular structure of 
the nasal mucosa [17].  
Another polymer that can be used as gel-based is gelrite. Gelrite is 
made in 3 concentration (0.5%, 0.75%, and 1%) using ketorolac 
tromethamine as active compound. The result shows that in the 
concentration of 0.75% w/v, gelrite was found to be a better carrier 
system since it shows optimum gelation. The increase of gelrite 
concentration makes the gelation capacity also increases. In the in 
vitro dissolution test, simulated tear fluid (basic media at pH 7.4) 
was selected as media for the dissolution studies. Ion activated 
ocular gel with 0.75% w/v of Gelrite concentrations showed the 
highest dissolution rate (86.96% within 6 h). The ocular irritancy 
studies indicate that the formulation was a non-irritant and very 
well tolerated by the eye. No ocular damage or abnormal clinical 
signs to the cornea, iris, or conjunctivae were visible. Corneal 
permeation studies were performed using isolated goat’s cornea on 
Franz diffusion cell using STF (pH 7.4) at 34±0.5 °C. the result is the 
percentage of drug release within 5 h is 86.79% [27]. 
In the other experiment, gelrite polymer also tested in various 
concentration between 0.2%-0.8%. Clarity of all formulations was 
found to be satisfactory. The pH within an acceptable range and 
hence would not cause any irritation upon administration of the 
formulation. The result of drug content for all formulation was found 
to be in acceptable range (72-86%). The formulation F6 (0.7%) has 
an optimum viscosity (1985 cps) before gelation which will allow its 
installation into the eye as a liquid this will then undergo rapid sol-
gel transition due to ion exchange and the viscosity after gelation 
was found to be 4520 cps. The results of F6 in vitro release studies 
showed better sustaining effect amongst all formulation. This may 
be due to the higher concentration of gelrite. The formulation F6 
passed the sterility test (no turbidity in more than 7 d) [28].  
Sodium alginate and carbopol also can be used as gel based. In situ 
gel forming systems were prepared using sodium alginate and 
carbopol 934 at different concentrations along with HPMC as a 
viscosity enhancing agent. The maximum concentration of sodium 
alginate used was 2% and carbopol was 0.12 % to develop gel 
systems of flurbiprofen (0.03% in all formulation). The result can be 
concluded that polymer combination 2% alginate and 0.4% HPMC 
showed better potential for sustained topical drug delivery to eyes 
for rational drug therapy as supported by in vivo test studies [22]. 
To achieve effective ocular therapy, a sufficient number of active 
ingredients must be delivered and maintained at the site of action in the 
eye. To increase the availability of eye medication, there is a great effort 
directed to the newer drug delivery system for eye administration. 
Conventional delivery systems often produce poor bioavailability and 
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therapeutic responses because of high fluid replacement of tears and 
dynamics leads to rapid removal of the drug from the eye. New research 
in the drug delivery system is directed at incorporating several drug 
delivery technologies, which include building systems that not only 
prolong delivery contact time on the ocular surface but which at the 
same time slows down the elimination of the drug. There are various 
new dosage forms such as Insitu gel, collagen shield, minidisc, ocular 
film, ocusert, nanosuspension, nanoparticulate system, liposome, 
niosome, dendrimer, octopus, etc. Thus, to overcome the bioavailability 
problem, in situ intalmic gel was developed. The various temperatures, 
pH, and ions that induce in situ polymeric systems used to achieve long 
contact time with the cornea and increase its bioavailability make 
optimizing ocular therapy [29].  
Although various formulations exist in the market for ocular drug 
delivery but still unable to provide the highest bioavailability 
associated with the given dose. Whenever ophthalmic drugs are 
applied through conventional dosage forms to the anterior segment 
of the eye, only a small number (5%) actually penetrate the cornea 
and reach the interior tissue of the eye. Affecting factors the 
bioavailability of the drug include rapid solution drainage by gravity, 
induced lachrymation, flashing reflexes, normal tear shift, superficial 
drug absorption to the conjunctiva and sclera, rapid removal by 
peripheral blood flow and low corneal permeability (acting as a 
barrier lipids). Advances have been made in gel technology for the 
development of droppable gels. They are liquid as they gradually 
and undergo phase transitions in the ocular cul-de-sac to form visco-
elastic gels and this responds to environmental changes [30]. The 
systemic absorption of the drug dried through the nasolacrimal ducts 
may cause some undesirable side effects. To overcome these problems, 
inhthalmic eye gel has been investigated in an attempt to extend the 
ocular dose of drugs for topical applications in the eye [31].  
CONCLUSION 
An osmotic gradient is a factor that determines the rate of gelation 
and polymers play an important role in drug delivery from their 
dosage forms. Polymeric in gelling systems provides longer drug 
release compared to conventional delivery systems. 
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